Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine is an experimental small molecule compound belonging to the phenyl-1,2,4-triazole class. It has not been approved for any indication and is primarily studied in preclinical research. The compound acts as a potent inhibitor of serine/threonine-protein kinase pim-1 (PIM1), with a reported Ki of 11 nM. PIM kinases are implicated in cell survival and proliferation pathways and are considered potential targets in oncology drug discovery. No clinical trials or approved uses have been reported for this molecule[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine.